211 related articles for article (PubMed ID: 30686493)
21. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
[TBL] [Abstract][Full Text] [Related]
22. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes.
Everett BM; Donath MY; Pradhan AD; Thuren T; Pais P; Nicolau JC; Glynn RJ; Libby P; Ridker PM
J Am Coll Cardiol; 2018 May; 71(21):2392-2401. PubMed ID: 29544870
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness evaluation of the 45-49 year old health check versus usual care in Australian general practice: A modelling study.
Si S; Moss J; Karnon J; Stocks N
PLoS One; 2018; 13(11):e0207110. PubMed ID: 30412596
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness of Canakinumab From a Canadian Perspective for Recurrent Cardiovascular Events.
Boczar KE; Beanlands R; Wells G; Coyle D
CJC Open; 2022 May; 4(5):441-448. PubMed ID: 35607490
[TBL] [Abstract][Full Text] [Related]
25. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.
Lamotte M; Annemans L; Evers T; Kubin M
Pharmacoeconomics; 2006; 24(2):155-69. PubMed ID: 16460136
[TBL] [Abstract][Full Text] [Related]
26. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.
Kazi DS; Penko J; Coxson PG; Guzman D; Wei PC; Bibbins-Domingo K
Ann Intern Med; 2019 Feb; 170(4):221-229. PubMed ID: 30597485
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
JAMA Cardiol; 2017 Oct; 2(10):1069-1078. PubMed ID: 28832867
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; Hout BV
Clin Ther; 2017 Apr; 39(4):771-786.e3. PubMed ID: 28366593
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial.
Magnuson EA; Li H; Wang K; Vilain K; Shafiq A; Bonaca MP; Bhatt DL; Cohen M; Steg PG; Storey RF; Braunwald E; Sabatine MS; Cohen DJ;
J Am Coll Cardiol; 2017 Aug; 70(5):527-538. PubMed ID: 28750695
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of optimizing use of statins in Australia: using outpatient data from the REACH Registry.
Ademi Z; Reid CM; Hollingsworth B; Stoelwinder J; Steg PG; Bhatt DL; Vale M; Liew D;
Clin Ther; 2011 Oct; 33(10):1456-65. PubMed ID: 21982384
[TBL] [Abstract][Full Text] [Related]
33. Are Office-Based Workplace Interventions Designed to Reduce Sitting Time Cost-Effective Primary Prevention Measures for Cardiovascular Disease? A Systematic Review and Modelled Economic Evaluation.
Gao L; Nguyen P; Dunstan D; Moodie M
Int J Environ Res Public Health; 2019 Mar; 16(5):. PubMed ID: 30866495
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
35. Canakinumab for secondary prevention of coronary artery disease.
Ortega-Paz L; Capodanno D; Angiolillo DJ
Future Cardiol; 2021 May; 17(3):427-442. PubMed ID: 33533289
[TBL] [Abstract][Full Text] [Related]
36. Offering a lifestyle intervention to women of premenopausal age as primary prevention for cardiovascular disease? - assessing its cost-effectiveness.
Gao L; Moodie M
Int J Behav Nutr Phys Act; 2022 Dec; 19(1):152. PubMed ID: 36517831
[TBL] [Abstract][Full Text] [Related]
37. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
[TBL] [Abstract][Full Text] [Related]
38. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.
Roman YM; Hernandez AV; White CM
Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120
[TBL] [Abstract][Full Text] [Related]
39. Canakinumab for secondary prevention of atherosclerotic disease.
Capodanno D; Angiolillo DJ
Expert Opin Biol Ther; 2018 Feb; 18(2):215-220. PubMed ID: 29265905
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
